Recommendation of the President – Veoza (fezolinetant)

On 6 September 2024, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 91/2024 on the appropriateness of issuing approvals for the reimbursement of the medicinal product Veoza (fezolinetant) for the indication: treatment of moderate to severe vasomotor symptoms associated with menopause

Publication in Public Information Bulletin (BIP) >>